Upper urinary tract transitional cell carcinoma (UUT-TCC) is quite an uncommon disease, and its prognosis differs among individuals irrespective of tumor stage. DNA repair gene polymorphisms are reported to result in the modulation of the repair capacity and might influence the prognosis of UUT-TCC. We examined the associations between functional polymorphisms in five DNA repair genes, and the prognosis of UUT-TCC in 103 UUT-TCC patients. Variant alleles in xeroderma pigmentosum complementation group C, more than three total variant alleles in all DNA repair genes studied and more than two total variant alleles in three nucleotide excision repair genes were independently associated with improved overall and disease-specific survival of UUT-TCC patients in multivariate analysis (P = .0063 and P = .0005 for xeroderma pigmentosum complementation group C, P = .016 and P = .0016 for all genes, and P = .0053 and P = .018 for nucleotide excision repair genes, respectively). These results suggest that some DNA repair gene polymorphisms may preoperatively be valuable as prognostic factors for UUT-TCC beyond tumor stage and grade, helping to provide optimal treatment strategies for individual patients. Neoplasia (2008) 10, 255-265 
Introduction
Upper urinary tract transitional cell carcinoma (UUT-TCC), which arises from the renal pelvis or ureter, is quite an uncommon disease, accounting for only 5% of all cases of urothelial carcinoma [1] . Although the standard treatment for localized UUT-TCC is surgical resection, local recurrence or distant metastasis sometimes occurs during the follow-up after surgery, and the survival rate at 5 years is less than 50% for patients with T2-T3 tumors [1] . Therefore, some patients with localized UUT-TCC need combined-modality therapy, chemotherapy, and/or radiotherapy and nephroureterectomy [2, 3] . Meanwhile, systemic chemotherapy is offered as a viable therapeutic option for patients with metastatic disease at the time of initial diagnosis. The survival rate at 5 years is normally less than 10% for patients with T4 or N+/M+ tumors [1] ; however, some of these patients have a response to therapy and a relatively long-term survival [4] . It is therefore acknowledged that the prognosis of UUT-TCC differs among individuals irrespective of tumor stage. Thus, although tumor stage and grade have been considered the main prognostic factors for UUT-TCC [1, 5] , more accurate prognostic markers may help to provide optimal treatment strategies for individual patients.
The complex system of DNA repair enzymes plays a vital role in protecting the genome from the consequences of exogenous and en-dogenous mutagenic exposure [6] . There are at least four known pathways of DNA repair, namely, base excision repair, nucleotide excision repair (NER), double-strand break (including homologous recombination and nonhomologous end-joining) repair, and mismatch repair, each of which operates on a specific type of damaged DNA and each of which involves numerous molecules [7] . Any decreased repair capacity of these enzymes causes alterations to the genome and subsequent cancer development [6] . There are several common polymorphisms in genes encoding DNA repair enzymes, and some of these polymorphisms are reported to result in subtle structural alterations in the repair enzyme and modulation of its repair capacity. The wild-type and variant genotypes of xeroderma pigmentosum complementation groups C (XPC ), D (XPD), and G (XPG) and X-ray repair cross-complementing groups 1 (XRCC1) and 3 (XRCC3) have been shown to be associated with different levels of DNA repair activity using various assays [8] [9] [10] [11] [12] [13] . In this manner, these polymorphisms may contribute to interindividual cancer susceptibility in the general population. The associations between DNA repair gene polymorphisms and bladder cancer risk or prognosis have been demonstrated in several reports [7, [14] [15] [16] [17] [18] [19] [20] . However, a study on the association of these polymorphisms with UUT-TCC is lacking.
Risk factors for UUT-TCC include cigarette smoking and exposure to certain industrial dyes or solvents [21] , and some of the DNA damage that may occur as a result of these factors would be repaired by the DNA repair enzymes. The accumulation of multiple genetic changes is considered to cause the development and progression of UUT-TCC, such as bladder TCC [22] [23] [24] . We previously reported associations between DNA repair gene polymorphisms and tumor stage, grade, p53 alteration, or prognosis in patients with bladder cancer [17, 18, 25] . These polymorphisms, as host genetic factors, may also influence the progression and prognosis of UUT-TCC due to the accumulation of multiple genetic changes caused by the modulated DNA repair capacity. In the current study, we investigated the associations between polymorphisms in the DNA repair genes, XPC (Lys939Gln, A/C), XPD (Lys751Gln, A/C), and XPG (Asp1104His, G/C) (involved in NER), XRCC1 (Arg399Gln, G/A) (involved in base excision repair), and XRCC3 (Thr241Met, C/T) (involved in double-strand break repair), and clinicopathologic parameters and survival in patients with UUT-TCC to determine the value of these polymorphisms as prognostic markers. Germline genetic polymorphisms are thought to be suitable markers for UUT-TCC patients, because polymorphisms are available without operation. The polymorphisms studied in this report were generally selected according to prior data on functional effects or reports of association with malignancies, to increase the likelihood of positive findings [7, 12, 26] , and we have consecutively investigated the effects of these polymorphisms on cancer biology [16] [17] [18] 25, 27] . In addition, we also examined the association of these polymorphisms with susceptibility to UUT-TCC in the present report, using the case-control study. To our knowledge, there have been few case-control studies on genetic polymorphisms, limited to UUT-TCC, to date.
Materials and Methods

Patients and Control Subjects
The study group comprised 103 patients (69 men and 34 women; median age, 70 years; age range, 44 to 93 years) with histopathologically confirmed UUT-TCC at Yamaguchi University Hospital, Ube, Japan, between August 1990 and June 2006. As control subjects, 215 healthy volunteers were chosen from the same geographical area (148 men and 67 women; median age, 67 years; age range, 29 to 87 years), as previously reported [27] . This study was approved by the institutional ethical committee at the Graduate School of Medicine, Yamaguchi University, and written informed consent was obtained from each patient and control. The characteristics of the UUT-TCC patients and control subjects, all of whom were native Jap-anese, are shown in Table 1 . Regarding control subjects, only age and gender were recorded as personal data. The tumor staging system was based on the American Joint Commission on Cancer staging system [28] , and the tumors were histopathologically graded according to the World Health Organization's classification. Of the 103 patients with UUT-TCC, 97 underwent an operation that was normally nephroureterectomy with removal of the bladder cuff. Platinum-based chemotherapy, radiotherapy, or both were performed in 24, 4, or 16 patients, respectively. Follow-up information was available for 100 of 103 patients with UUT-TCC. Of these, at a median follow-up of 36 months (mean, 44.5 months; range, 2 to 167 months), 39 and 24 suffered death from any cause and disease-specific death during the followup, respectively.
DNA Extraction and Genotyping
Peripheral blood samples were collected from each patient at initial diagnosis and from each control subject, and lymphocyte DNA was extracted using the QIAamp DNA Mini Kit (VWR International, West Chester, PA). Polymorphisms in XPC, XPD, XPG, XRCC1, and XRCC3 genes were genotyped using polymerase chain reaction (PCR)-restriction fragment length polymorphism. This method, including the primer sequences, PCR conditions, and restriction endonucleases for each polymorphism, has been described previously [12, 16, 18] . Briefly, the DNA fragments were amplified from 10 ng of DNA in 10 μl of PCR reactions containing 1.5 mM MgCl 2 , 0.2 mM each deoxyribonucleotide triphosphate, 0.3 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), and 0.3 μM each primer. The PCR products were digested with the appropriate restriction endonucleases that recognized and cut either wild-type or variant sequences at 37°C for at least 3 hours. The digested PCR products were electrophoresed on 2% agarose gels and were stained with ethidium bromide for visualization under ultraviolet light. To control the restriction digestion of the PCR products, genotyping assays were randomly repeated and results were checked for concordance. About 10% of the amplified fragments were also randomly checked by direct DNA sequencing and comparison of the PCR-restriction fragment length polymorphism and sequencing results showed 100% concordance in all experiments. Variant alleles were defined as Gln for XPC, Gln for XPD, His for XPG, Gln for XRCC1, and Met for XRCC3, according to previous reports [12, 16] .
Statistical Analysis
Differences in the genotype and allele frequencies of the DNA repair genes between the UUT-TCC cases and the control subjects, and associations between the genotypes and the clinicopathologic characteristics at the time of initial diagnosis of the UUT-TCC patients, were assessed for statistical significance using the chi-square analysis or two-sided Fisher's exact test; odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. P values less than .005 were considered to indicate statistical significance, because multiple comparisons were conducted [29] . Overall and disease-specific survival of the UUT-TCC patients were calculated from the day of initial diagnosis until the last follow-up or death from any cause and from UUT-TCC, respectively; patients who were alive at the last follow-up were censored at that time. The associations between categorical variables, including DNA repair genotypes, and survival were estimated by calculating the hazard ratios (HRs) with 95% CIs using Cox proportional hazard regression models. In addition, overall and disease-specific survival was analyzed by plotting Kaplan-Meier curves, and the survival probability distributions were compared using the log-rank test. Because the prognosis of cancer patients likely involves multistep, multigenic pathways, it is unlikely that any one single genetic polymorphism would have a dramatic effect on clinical outcome, and it is important to undertake a pathway-based analysis of multiple polymorphic genes [19] . Thus, we also analyzed the numbers of total variant alleles in all DNA repair genes studied and in NER genes (XPC, XPD, and XPG). P values less than .05 were considered to indicate statistical significance in these tests and variables with P < .05 in univariate analysis were also assessed for their relationship with survival by multivariate analysis. Data were processed using JMP software (SAS Institute Inc., Cary, NC).
Results
Genotype and Allele Frequencies of the DNA Repair Genes in UUT-TCC Cases and Control Subjects
The genotype frequencies of the XPC, XPD, XPG, XRCC1, and XRCC3 genes, in both the 103 UUT-TCC cases and the 215 control subjects, were found to be in Hardy-Weinberg equilibrium. The genotype and allele frequencies in cases and controls are shown in Table 2 . The Lys/Gln + Gln/Gln genotypes of the XPD gene were less frequent in cases than in controls (OR: 0.26, 95% CI: 0.061-0.77, P = .032; OR adjusted for age and gender: 0.29, 95% CI: 0.067-0.89, P = .053; two-sided Fisher's exact test). The Gln alleles of the XPD gene were also less frequent in cases than in controls (OR: 0.24, 95% CI: 0.072-0.80, P = .013; two-sided Fisher's exact test). However, these differences were not statistically significant when considering multiple comparisons (see Materials and Methods section). No significant differences in genotype or allele frequencies, between cases and controls, were observed for the other polymorphisms in the XPC, XPG, XRCC1, or XRCC3 genes.
Association Between DNA Repair Genotypes and Age, Gender, Tumor Stage, and Grade in UUT-TCC Patients
The associations between DNA repair genotypes and age, gender, tumor stage, and grade, in UUT-TCC patients, are presented in Table 3 . His/His genotypes of the XPG gene were more frequent than Asp/Asp (OR: 4.5, 95% CI: 1.1-18, P = .038) or Asp/Asp + Asp/His (OR: 2.4, 95% CI: 1.0-5.8, P = .045) genotypes in female patients with UUT-TCC. In addition, Gln/Gln genotypes of the XPC gene were less frequent than Lys/Lys (OR: 0.23, 95% CI: 0.066-0.83, P = .032) or Lys/Lys + Lys/Gln (OR: 0.30, 95% CI: 0.10-0.91, P = .028) genotypes in patients with T2/T3/T4 tumors. However, these associations were not statistically significant. There were no significant associations between DNA repair genotypes and patient age or tumor grade.
Univariate Analysis of DNA Repair Genotypes and Overall Survival of UUT-TCC Patients
A univariate Cox regression analysis for predicting the overall survival of UUT-TCC patients is presented in Table 4 . XPC and XPG genotypes, and the numbers of total variant alleles in all DNA repair genes studied and in NER genes, were associated with the probability of overall survival in UUT-TCC patients. Patients with Gln/Gln or Lys/Gln + Gln/Gln genotypes of the XPC gene had significantly improved overall survival compared with those with Lys/Lys genotypes (HR: 0.48, 95% CI: 0.25-0.80, P = .0041 for Gln/Gln; HR: 0.60, 95% CI: 0.43-0.84, P = .0032 for Lys/Gln + Gln/Gln). In addition, patients with more than two variant alleles in NER genes had significantly improved overall survival compared with those with two or less variant alleles (HR: 0.45, 95% CI: 0.22-0.76, P = .0011). Overall survival was plotted for the Lys/Gln + Gln/Gln genotypes of the XPC gene, His/His genotypes of the XPG gene, more than three variant alleles in all DNA repair genes and more than two variant alleles in NER genes, compared with the remaining groups, using Kaplan-Meier survival curves (Figure 1 , A-D, respectively). These genotypes were associated with improved overall survival (P = .0016 for the XPC gene, P = .016 for the XPG gene, P = .019 for the total variant alleles in all DNA repair genes, and P = .0035 for the total variant alleles in NER genes; log-rank test). Clinicopathologic variables were also assessed for their relationship with the overall survival of UUT-TCC patients by univariate analysis (Table 4 ). Tumor stage (T2/T3/ T4), distant metastasis and grade (G3) were associated with an unfavorable outcome. 
Multivariate Analysis of DNA Repair Genotypes and Overall Survival of UUT-TCC Patients
Univariate Analysis of DNA Repair Genotypes and Disease-Specific Survival of UUT-TCC Patients
A univariate Cox regression analysis for predicting the diseasespecific survival of UUT-TCC patients is presented in Table 5 . XPC genotypes, and the numbers of total variant alleles in all DNA repair genes and in NER genes, were significantly associated with the probability of disease-specific survival in UUT-TCC patients. Patients with Gln/Gln genotypes of the XPC gene had significantly improved disease-specific survival compared with those with Lys/Lys genotypes (HR: 0.32, 95% CI: 0.076-0.74, P = .0039). In addition, patients with more than three variant alleles in all DNA repair genes had significantly improved disease-specific survival compared with those with three or less variant alleles (HR: 0.43, 95% CI: 0.17-0.80, P = .0048), and patients with more than two variant alleles in NER genes also had significantly improved disease-specific survival compared with those with two or less variant alleles (HR: 0.32, 95% CI: 0.076-0.70, P = .0015). Disease-specific survival was plotted for the Lys/Gln + Gln/Gln genotypes of the XPC gene, His/His genotypes of the XPG gene, more than three variant alleles in all DNA repair genes and more than two variant alleles in NER genes, compared with the remaining groups, using Kaplan-Meier survival curves (Figure 2 , A-D, respectively). These genotypes were associated with improved disease-specific survival, except for XPG gene (P = .0032 for the XPC gene, P = .069 for the XPG gene, P = .012 for the total variant alleles in all DNA repair genes, and P = .0066 for the total variant alleles in NER genes; log-rank test). Clinicopathologic variables were also assessed for their relationship with the diseasespecific survival of UUT-TCC patients by univariate analysis (Table 5 ). Tumor stage (T2/T3/T4), lymph node metastasis, distant metastasis, and grade (G3) were associated with an unfavorable outcome.
Multivariate Analysis of DNA Repair Genotypes and Disease-Specific Survival of UUT-TCC Patients
Using multivariate analysis (model one) including all factors with P < .05 in univariate analysis (tumor stage, lymph node metastasis, distant metastasis, grade, and XPC genotypes), XPC genotypes (HR: 0.37, 95% CI: 0.19-0.65, P = .0005), as well as distant metastasis, were independently associated with disease-specific survival ( Table 5 ).
The XPC genotypes were the most powerful prognostic markers, followed by distant metastasis (HR: 6.6, 95% CI: 1.7-22, P = .0069). When the number of variant alleles in all DNA repair genes was used instead of XPC genotypes (model two), the number of variant alleles (HR: 0.31, 95% CI: 0.073-0.70, P = .0016), as well as distant metastasis, was independently associated with disease-specific survival. When the number of variant alleles in NER genes was used instead of XPC genotypes (model three), the number of variant alleles (HR: 0.39, 95% CI: 0.090-0.87, P = .018), as well as tumor stage and distant metastasis, was independently associated with disease-specific survival.
Discussion
In the present study, we found that some DNA repair genotypes were independently associated with the overall or disease-specific survival of UUT-TCC patients beyond tumor stage and grade. Recently, there have been some reports that have assessed molecular markers for their independent prognostic potential in patients with UUT-TCC [5, [30] [31] [32] . However, most of these series include 80 cases or less, and the power may be limited in the analyses. In addition, almost all of the reported molecular markers need tumor tissue samples obtained by operation and complex techniques [5, [30] [31] [32] , unlike the evaluation of germline genetic polymorphisms, which requires little more than a peripheral blood sample and standard PCRs, making these tests potentially useful in the clinical setting [33] . In UUT-TCC, it is difficult to obtain enough tumor tissue samples for the molecular analyses on biopsy. DNA repair genotypes may therefore be preoperatively valuable as prognostic factors for UUT-TCC.
Recently, Brown et al. [34] emphasized the importance of neoadjuvant chemotherapy as a first-line strategy for localized UUT-TCC patients with a high risk of recurrence or metastasis, to improve the outcome; however, they also mentioned the absence of a useful marker for risk assessment. Patients with UUT-TCC often sustain a significant loss of renal reserve as a result of nephroureterectomy, frequently in the setting of advanced age or chronic renal insufficiency. This factor essentially precludes the ability to deliver effective doses of cytotoxic chemotherapy after surgery [4] . The DNA repair genotypes could therefore be helpful in preoperative patient selection for neoadjuvant chemotherapy for UUT-TCC. Predicting the prognosis of UUT-TCC based on DNA repair genotypes might help to stratify the patients by their risk of progression and to provide personalized treatments and follow-up strategies.
In this study, some DNA repair gene polymorphisms potentially influenced the malignant phenotypes of UUT-TCC. This result may be due to the modulated DNA repair capacity caused by the DNA repair gene polymorphisms. Various assays have been developed to quantify DNA repair activity for DNA repair gene polymorphisms, including the Comet assay and the host cell reactivation assay [9, 33] .
Despite some inconsistencies in the literature, it seems likely that the wild-type and variant genotypes are associated with different levels of DNA repair activity [8] [9] [10] [11] [12] . Our patients with variant alleles in the XPC gene, those with more than three total variant alleles in all DNA repair genes studied and those with more than two total variant alleles in NER genes had significantly improved survival. The wild-type genotypes conferring suboptimal DNA repair in the tumor might lead to the accumulation of multiple genetic changes and to biologically more aggressive UUT-TCC. It has been shown that the wild-type genotypes of the XPC, XPD, XPG, and XRCC1 genes are associated with decreased DNA repair capacity [8, [10] [11] [12] , and these results are in accord with our findings.
On the contrary, another study showed that genetic polymorphisms in NER pathway could explain only a small amount of the variability in DNA repair capacity using an assay measuring the removal of in vitro-induced benzo[a]pyrene diolepoxide-DNA adducts in lymphoblastoid cells in sisters discordant for breast cancer from the New York Registry [35] . Although the accurate cause for the discrepancy in the findings between this and our studies is uncertain, it might be due to the differences in ethnic backgrounds, methods for DNA repair capacity assay, or cancer types.
DNA repair gene polymorphisms potentially influenced malignant phenotypes of UUT-TCC in our present study, although they were germline variations not somatic mutations in tumor cells. Loktionov [36] demonstrated that both cancer initiation risk and later neoplastic events (tumor growth, invasion, metastatic spread, response to therapeutic interventions, and finally, survival) are strongly affected by factors that are predetermined by the individual's genetic background. Hunter [37] also stated that recent evidence implies a significant role of germline polymorphisms in cancer progression. Germline polymorphisms may play an important role in cancer progression because cancer development and progression strongly depend on altered interactions between malignant cells and their normal neighbors [27] .
Because the population of our UUT-TCC patients had heterogeneity with multiple stages and therapies, we included these factors as categorical variables in multivariate analyses for survival using Cox proportional hazard regression models. In these analyses, some DNA repair genotypes were found to be independently associated with survival beyond tumor stage and grade, whereas therapeutic modalities did not significantly affect the survival. If our findings that the modulated DNA repair capacity caused by the DNA repair genotypes might have a significant impact on the survival of UUT-TCC patients are confirmed in functional and larger studies, modification of the DNA repair enzyme level or DNA repair pathway signaling might be a novel therapeutic target for UUT-TCC.
In the case-control study, no significant associations were observed between DNA repair genotypes and individual risk for UUT-TCC. We have therefore concluded this study to be negative, with respect to UUT-TCC susceptibility. However, the sample size was limited to detect these associations, and larger studies are needed, including the analysis of smoking status both in cases and controls, such as some other types of cancer [14, 15, 38, 39] . Concerning bladder cancer, there have been several reports on the significant associations between DNA repair genotypes and risk or progression [7, [14] [15] [16] [17] [18] [19] [20] 38] . Sanyal et al. [20] showed that bladder cancer patients that were simultaneous carriers of variant alleles at the XPD (Lys751Gln) and XPC (Lys939Gln) polymorphisms were at lower risk of death than other patients (P = .001). This result is partly compatible with our findings in UUT-TCC patients. Cigarette smoking and exposure to certain industrial dyes or solvents are associated with an increased risk of UUT-TCC, similar to bladder TCC [21] . However, phenacetin-containing analgesics and Balkan nephropathy are stronger risk factors for UUT-TCC than for bladder TCC [40, 41] . In addition, UUT-TCC is associated with hereditary nonpolyposis colorectal cancer (HNPCC), because UUT-TCC occurs at a higher rate in patients with HNPCC [42, 43] . Microsatellite instability, which is a well-established feature of HNPCC [44] , appeared to be at a high level in patients with UUT-TCC, whereas it is a rare event in those with bladder TCC [43, 45, 46] . Thus, there are a few, but substantial, differences in the etiology and genetic alterations between UUT and bladder TCCs. Comparing the associations between DNA repair polymorphisms and cancer risk and prognosis in patients with UUT-TCC, with those in patients with bladder TCC, might provide a better understanding of the mechanism underlying the development and progression of UUT-TCC.
In conclusion, our study provides evidence that some DNA repair genotypes are independently associated with survival and may preoperatively be valuable as prognostic factors for UUT-TCC beyond tumor stage and grade, possibly due to altered DNA repair capacity caused by these polymorphisms. However, our results with a limited sample size allow only preliminary conclusions, and larger studies are needed to confirm the associations between DNA repair gene polymorphisms and the clinical outcomes of patients with UUT-TCC.
